Radiopharm licences a dual action LRRC15-targeting monoclonal antibody

Radiopharm Theranostics (ASX:RAD), a developer of radiopharmaceutical products for both diagnostic and therapeutic uses, has announced an exclusive agreement with University of California Los Angeles (UCLA) Technology Development Group (UCLA-TDG) to license UCLA’s LRRC15 antibody “DUNP19.

The licence agreement is effective immediately and extends to the expiration or abandonment of the applicable patent rights.

Radiopharm claims that the DUNP19 antibody has a unique ability to effectively find, internalise and destroy both cancer and TME cells.

Clinical development pipeline

The licensing agreement gives Radiopharm the rights to develop DUNP19 as an Antibody-Drug Conjugates (ADC) within radiotherapy as part of its clinical development pipeline.

Commenting in today’s announcement, Radiopharm’s CEO Riccardo Canevari said:

“We are excited to have entered into the licensing agreement with UCLA and to have added DUNP19, a breakthrough dual action monoclonal antibody, to our clinical development pipeline.”

“DUNP19 has demonstrated promise for several indications, but its potential as first in class therapy for osteosarcoma is particularly exciting, considering the high unmet need in the children and adolescents who typically suffer this disease.”

Radiopharm’s share price traded flat following the announcement today.

Radiopharm’s share price has been losing ground for some time.